Literature DB >> 25656962

The excess health care costs of KardioPro, an integrated care program for coronary heart disease prevention.

Christian Becker1, Rolf Holle2, Björn Stollenwerk2.   

Abstract

Coronary heart disease (CHD) is a major cause of death and important driver of health care costs. Recent German health care reforms have promoted integrated care contracts allowing statutory health insurance providers more room to organize health care provision. One provider offers KardioPro, an integrated primary care-based CHD prevention program. As insurance providers should be aware of the financial consequences when developing optional programs, this study aims to analyze the costs associated with KardioPro participation. 13,264 KardioPro participants were compared with a propensity score-matched control group. Post-enrollment health care costs were calculated based on routine data over a follow-up period of up to 4 years. For those people who incurred costs, KardioPro participation was significantly associated with increased physician costs (by 33%), reduced hospital costs (by 19%), and reduced pharmaceutical costs (by 16%). Overall costs were increased by 4%, but this was not significant. Total excess costs per observation year were €131 per person (95% confidence interval: [€-36.5; €296]). Overall, KardioPro likely affected treatment as the program increased costs of physician services and reduced costs of hospital services. Further effects of substituting potential inpatient care with increased outpatient care might become fully apparent only over a longer time horizon.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Delivery of health care; Health; Health care costs; Health care reform; Insurance; Integrated; Primary health care

Mesh:

Year:  2015        PMID: 25656962     DOI: 10.1016/j.healthpol.2015.01.012

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  1 in total

1.  Being treated in higher volume hospitals leads to longer progression-free survival for epithelial ovarian carcinoma patients in the Rhone-Alpes region of France.

Authors:  Marius Huguet; Lionel Perrier; Olivia Bally; David Benayoun; Pierre De Saint Hilaire; Dominique Beal Ardisson; Magali Morelle; Nathalie Havet; Xavier Joutard; Pierre Meeus; Philippe Gabelle; Jocelyne Provençal; Céline Chauleur; Olivier Glehen; Amandine Charreton; Fadila Farsi; Isabelle Ray-Coquard
Journal:  BMC Health Serv Res       Date:  2018-01-04       Impact factor: 2.655

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.